Introduction
Chronic kidney disease (CKD) is increasingly recognized as being prevalent in all countries. CKD is associated with adverse cardiovascular disease (CVD) outcomes, and CKD patients are more likely to die, predominantly of CV events, than to reach end-stage kidney disease [1] [2] [3] . Factors that contribute to both progressive kidney disease and the associated cardiovascular morbidity have been increasingly identifi ed and are often similar. The complex biological processes associated with both conditions share a common target: the vascular bed. Thus, the coincident existence of both conditions is more readily explainable.
This paper attempts to describe the current understanding of the pathophysiology of CVD in CKD, with specifi c focus on new insights into hormonal, immunomodulatory and non-traditional risk factors, and most specifi cally, the interaction between factors. The integration of understanding basic processes and their translation into clinical strategies is important if we are to impact the outcomes of individuals living with kidney disease.
The biological processes that are involved in progressive CKD and CVD center around cell damage which is incited by and incites infl ammation, which subsequently leads to fi brosis, apoptosis and cell repair. Overall, recurrent damage leads to dysregulated balance between the complex systems of infl ammation and repair, such that progressive kidney function decline occurs. It is intriguing that many of the hormonal and cytokine derangements described in kidney disease can be viewed as both causal and the effect of loss of kidney function. The vascular disease that characterizes progressive CKD is not limited to the glomerulus, but also involved other vascular beds within the individuals. Thus, the processes mitigating progressive kidney damage are most likely those contributing to excessive cardiovascular disease.
In addition to the usual factors contributing to pathological processes (hypertension, diabetes, dyslipidemia), it is becoming evident that specifi c factors such as hormones, chemokines and cytokines are important. The key players in these processes include hormones, such as angiotensin II, aldosterone, cortisal, vitamin D and erythropoietin, infl ammatory cytokines, such as interleukin (IL)-6, transforming growth factor-␤ , tumor necrosis factor-␣ and C-reactive protein, and adhesion molecules, such as vascular cell adhesion molecule and intracellular adhesion molecule. In addition, proteins involved in reparative processes such as bone morphogenic protein-7, growth factor and insulin-derived growth factor have also been described in the context of progressive CVD and CKD.
It is beyond the scope of this paper to describe in detail all the factors associated with progressive CKD and CVD; specifi cally, we will not discuss hypertension, proteinuria and dyslipidemia per se. Furthermore, there is extensive information on each of the hormones, cytokines and chemokines, which cannot be covered. However, it is our intention to describe key interactions that may be of specifi c clinical relevance, with a focus on vitamin D, aldosterone and erythropoietin as key hormones and immunoregulators of essential cell functions.
Consequences of Kidney Damage and Reduced Glomerular Filtration Rate
Low glomerular fi ltration rate (GFR) confers a poor outcome in numerous populations studied [3] . Most of the observational data gleaned from diverse or selected populations have relied on limited data from administrative data sets. Thus, while it is well known that the prevalence of associated abnormalities, such as hemoglobin, calcium, phosphate, parathyroid hormone (PTH), blood pressure and infl ammatory markers, are altered in CKD [4] [5] [6] [7] [8] [9] , the complexity of the impact of those alterations is underappreciated and undertreated.
In patients with CKD, both atherosclerotic and arteriosclerotic processes occur, triggered by different events, but ultimately culminating in impaired endothelial cell function. While ischemic disease is certainly prevalent, stiffening of the arterial vessels leading to an increase in left ventricular stress and pressure, subsequent hypertrophy, and ultimately, cardiomyopathy contributes to the high prevalence of heart failure and sudden death seen in CKD populations. The atherosclerotic process has recently been described as an infl ammatory process in which endothelial damage incites a cascade of events ultimately leading to plaque formation [10] [11] [12] [13] . Importantly, CKD patients irrespective of stage have evidence of activated infl ammatory processes both prior to and on dialysis. This infl ammatory state of uremia is likely the cornerstone of progressive vascular disease.
The arteriosclerotic process is driven by a combination of factors including aging, collagen loss, apoptosis, and subsequently, medial calcifi cation, all of which lead to increased vessel stiffness [14, 15] . These processes appear to be exacerbated, or perhaps even initiated, in the context of infl ammation, but are driven by a series of events which are biochemically and hormonally mediated.
Reduction in GFR is accompanied quite early on by reduced levels of a number of hormones and dysregulation of processes which are important in cell repair. Specifi cally, vitamin D production/hydroxylation to active forms is reduced, loss of erythropoietin synthesis occurs, and activation of the renin angiotensin aldosterone system is evident.
Vitamin D
Vitamin D has recently been determined to have a number of non-bone-related actions. Specifi cally, it has been shown to be an inhibitor of various aspects of infl ammation, an antiproliferative hormone for myocardial cell hypertrophy, and a negative endocrine regulator of the renin-angiotensin system (RAS) [16, 17] .
Vitamin D receptors (VDRs) are found in all organs, including the heart, vascular walls, kidney and immune cells. The VDR is a ligand-activated transcriptional factor which regulates a number of genes concerned with calcium phosphate and other physiologic processes as well.
The infl ammatory response which culminates in cytokine release (IL-1, IL-4, IL-6, TNF-␣ ) by macrophages and T cells induces smooth muscle cell proliferation and plaque formation. All of these processes can be inhibited by vitamin D and stimulated by high PTH and high phosphate. Interestingly, vitamin D is immunoregulatory in that it can downregulate infl ammatory cells and upregulate anti-infl ammatory cells (e.g., IL-10), such that an anti-infl ammatory cytokine profi le is produced [18] . Vitamin D also modulates the expression of tissue matrix metalloproteinases (MMPs), which are connective tissue enzymes secreted by activated macrophages during infl ammation. MMPs are involved in vascular remodeling. Interestingly, MMP-9 levels have been inversely correlated to vitamin D levels [19] . Low vitamin D levels have also been associated with increased cardiac calcifi cation, and higher levels of vitamin D with lower C-reactive protein and higher endothelial progenitor cell levels. Small clinical studies have described the regression of left ventricular hypertrophy in hemodialysis patients with administration of vitamin D [20, 21] . This observation is supported by cell data describing the inhibition of cell proliferation in neonatal rat myocytes with activated preparation of vitamin D.
Lastly, vitamin D defi ciency has been described in association with hypertension and high renin states. In mice models of VDR knock-out mice, higher levels of renin and angiotensin II have been described in association with left ventricular hypertrophy and hypertension [22] [23] [24] [25] [26] .
Thus, it appears that vitamin D defi ciency, a frequent accompaniment of early kidney disease, and loss of GFR may have a number of key roles in the pathogenesis of CVD.
Erythropoietin
The extrahematological effects of erythropoietins have been well described in recent publications [27, 28] . As an antiapoptotic, anti-infl ammatory hormone, it is important in the regulation of the balance of cell injury and repair. Erythropoietin defi ciency has been linked to reduced red cell survival, vascular health, neuronal health, renal tubular injury during ischemia and impaired neovascularization. In whole organism and patient studies, erythropoietin is important in maintaining red cell mass, cognitive function, exercise capacity, and possibly, protecting vital organs against ischemic damage.
Of late, the relationship between vitamin D and anemia has been described in a number of associative or small studies. In the presence of vitamin D, erythropoietic hormone requirements are reduced, and hemoglobin levels rise. This effect appears most prominent in patients with elevated PTH, but has been described across the spectrum. Given the previous discussions on anti-infl ammatory properties of vascular disease and the known erythropoietin resistance in the presence of infl ammation and hyperparathyroidism, this relationship warrants further careful study.
Aldosterone and Activation of the RAS
While the activation of the RAS system has long been known to adversely impact both kidneys and hearts, the specifi c action of each component has been more recently described. Given the plethora of information available on angiotensin inhibition and the widespread use of both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, we will focus on a less often discussed member of the cascade, namely aldosterone.
The role for aldosterone as a deleterious hormone for CVD has been described, specifi cally as a potent inducer of myocardial fi brosis, and the use of antagonists for patients with symptomatic heart failure is recommended [29] [30] [31] .
There is experimental evidence that aldosterone contributes to the development of glomerulosclerosis. Quinkler et al. [31] have quantifi ed a number of aspects of aldosterone action in human biopsies and determined that aldosterone/mineralcorticoid receptor activation is related to infl ammation and proteinuria.
Interestingly, McCarty [32] has recently hypothesized that through complex mechanisms, high protein diets leading to metabolic acidosis may contribute to hypercortisol and hyperaldosterone states. These in turn may promote visceral obesity and ultimately increase insulin resistance and the potential for type II diabetes. Metabolic acidosis promotes excretion of hydrogen ion via the induction of glutamine, which secondarily increases adrenocorticotropic hormone levels. It is these higher levels of adrenocorticotropic hormone which may lead to a cascade of hormonal events as described above, designed in the fi rst instance to improve ammonia excretion. This fascinating hypothesis adds credence to the importance of low protein diets as being protective for patients with CKD.
Cytokines and Chemokines
The role of various cytokines and biomarkers which describe the extent of cell injury have been the topic of multiple reviews and original research in the recent past.
The reader is referred to excellent papers by Stenvinkel [13] and Zoccali et al. [33] [34] [35] , which describe associations of specifi c biomarkers of infl ammation with patient outcomes.
Clinical Implications
To date, most clinical studies have focused on the modifi cation of the 'effects' of various hormones and processes. The focus has been on the endpoints of hormonal function (PTH level, hemoglobin level) instead of determining the complex interaction between the processes that regulate these easily measurable factors. Recent data suggest that the administration of vitamin D, irrespective of calcium phosphate and PTH levels, results in better outcomes [36, 37] ; further, that patients receiving erythropoiesis-stimulating agents have better outcomes than those who do not, and that those who respond to erythropoiesisstimulating agents with hemoglobin 1 12 g/dl have better outcomes [38] . Patients who have achieved best blood pressures and blockage of the RAS also have improved outcomes both prior to and on dialysis [39] [40] [41] .
In the context of current knowledge, we hypothesize that the imbalance of essential hormonal processes which impact on immunodulatory cytokine and chemokine release leads to an unchecked state of infl ammation, which propagates ongoing vascular disease. Subsequent abnormalities within the uremic milieu (including lack of inhibitors of calcifi cation, supersaturation with various compounds and ongoing shear stress/vascular endothelial cell injury) further propagate vascular disease.
The exocrine and endocrine functions of the kidney have been well described for years, but the interaction of loss of hormone synthesis and loss of GFR has not been well studied in the whole organism with respect to the direct and indirect impact on vascular health. A unifying hypothesis that explains the poor outcomes of patients with low GFR would be the loss of internal regulation of processes related to cell injury and repair. This simplifi cation of complex processes is an attempt to bring some rational approach to the care of patients with lower GFR.
It may be of key importance in individual patients to evaluate the extent of hormonal defi ciency and infl ammatory system activation, of course in the context of easily measured clinical parameters such as GFR level and blood pressure control. Perhaps, a few key medications which restore the internal balance (vitamin D, erythropoietin, aldosterone blockers, RAS blockers and/or anti-infl ammatories) should be considered fi rst-line treatment, in conjunction with appropriate diet restriction of key inciters of cell damage (protein/acid load and phosphate). A clearer understanding of the relative importance of each of these factors/strategies at each stage of CKD is important if we are to reduce the burden of CVD and CKD.
